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Abstract
Background: Previous studies have documented lower breast cancer survival among women with
lower socioeconomic status (SES) in the United States. In this study, I examined the extent to which
socioeconomic disparity in breast cancer survival was explained by stage at diagnosis, treatment,
race and rural/urban residence using the Surveillance, Epidemiology, and End Results (SEER) data.
Methods: Women diagnosed with breast cancer during 1998-2002 in the 13 SEER cancer registry
areas were followed-up to the end of 2005. The association between an area-based measure of SES
and cause-specific five-year survival was estimated using Cox regression models. Six models were
used to assess the extent to which SES differences in survival were explained by clinical and
demographical factors. The base model estimated the hazard ratio (HR) by SES only and then
additional adjustments were made sequentially for: 1) age and year of diagnosis; 2) stage at
diagnosis; 3) first course treatment; 4) race; and 5) rural/urban residence.
Results: An inverse association was found between SES and risk of dying from breast cancer (p <
0.0001). As area-level SES falls, HR rises (1.00 → 1.05 → 1.23 → 1.31) with the two lowest SES
groups having statistically higher HRs. This SES differential completely disappeared after full
adjustment for clinical and demographical factors (p = 0.20).
Conclusion:  Stage at diagnosis, first course treatment and race explained most of the
socioeconomic disparity in breast cancer survival. Targeted interventions to increase breast cancer
screening and treatment coverage in patients with lower SES could reduce much of socioeconomic
disparity.
Background
Previous studies have documented substantial disparities
in breast cancer survival in relation to socioeconomic sta-
tus (SES) as measured either at the individual [1,2] or area
levels [3-6] in the United States, with women in lower SES
groups showing poorer survival. Factors that may mediate
these disparities include differences in the stage at diagno-
sis, access to and quality of care delivered and other corre-
lates of low SES [7]. Women with less education and those
who are unemployed, reside in a poor area, or are unin-
sured or under-insured are more likely to be diagnosed at
later stages [8-10], and are less likely to receive optimal
cancer care [11,12]. Race has been reported to be related
with breast cancer survival independently of SES [5,13].
Limitations of most prior US studies that have examined
disparities in breast cancer survival by SES are that they
considered only women with early stage diagnosis [4,14-
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17] or those over age 65 years [1,4,9,13,17-19]. Other
studies involved patients at a single institution [2,14].
Therefore, they may not be representative of the entire
population diagnosed with breast cancer. In this study, I
examined the extent to which these disparities was
explained by stage at diagnosis, first course treatment, race
and rural/urban residence by taking account of these var-
iables, from the Surveillance, Epidemiology, and End
Results (SEER) database, simultaneously and including all
women diagnosed with breast cancer.
Methods
Study population
Women aged 15 years or older and diagnosed with first
primary invasive breast cancer (ICDO-3 code: C50) [20]
between January 1, 1998 and December 31, 2002 were
identified through the 13 population-based cancer regis-
tries in the United States that participated in the SEER pro-
gram (Atlanta, Connecticut, Detroit, Hawaii, Iowa, New
Mexico, San Francisco-Oakland, Seattle-Puget Sound,
Utah, Los Angeles, San Jose-Monterey, Rural Georgia and
the Alaska Native Registry). Of the 113,905 women, a
total of 1362 (1.2%) cases were excluded from the analy-
sis because they were diagnosed at autopsy or through
death certificate only (n = 705), had unknown race (n =
647) or missing residential address at diagnosis (n = 10).
Study variables
The outcome variable was survival time after diagnosis of
breast cancer. The primary study variable was a composite
measure of SES. As the SEER program does not collect
individual level measures of SES, a composite variable was
used based on two characteristics in county of residence:
"percent of adults with < 12 year education" and "percent
of families living below the federal poverty line". Data
were obtained from the 1990 U.S. Census. Educational
level was categorized into 4 similar size groups (1 → 4
from high to low) and poverty rate was divided into 3
major groups using the cutpoints: ≤ 9.9% (low), 10-
19.9% (medium), ≥ 20% (high) as recommended by oth-
ers based on empirical research [21]. Counties were
divided into four groups according to their levels of these
two SES measures so that each group had similar number
of cases. Counties with the educational level one (highest)
and lowest poverty rate was categorized as high SES; coun-
ties with either educational level one and medium poverty
rate, or lowest poverty rate and educational level two were
assigned to the upper middle SES group; counties with
educational level four and medium or high poverty rate,
or educational level three and high poverty rate were clas-
sified as the lowest SES group; the remaining combination
was the lower middle SES group. Women were allocated
into each of the SES groups according to the county they
lived in at diagnosis.
The following factors that may affect survival between SES
groups were included in the analysis. Year of diagnosis
were 1998 to 2002. Age at diagnosis was categorized into
5 groups: (15-44 years, 45-54 years, 55-64 years, 65-74
years and > = 75 years). Race was categorized into three
broad groups (White, Black and other). Rural/urban resi-
dence was defined based on the rural-urban continuum
codes for 2003 available at http://seer.cancer.gov/seerstat/
variables/countyattribs/ruralurban.html. Women were
categorized as living in an urban area if their county was
located in a metro area (code 1, 2, 3 on the continuum
codes). Stage at diagnosis, using American Joint Commit-
tee on Cancer (AJCC) stage [22], was categorized into 5
groups: stage I, II, III, IV and unknown stage or not appli-
cable. Number of lymph nodes positive for those having
lymph nodes examined was categorized into 3 groups:
none, 1-3, and ≥ 4 [23]. Information on the first course
treatment (surgery and/or radiation) was dichotomized
into receipt/no receipt categories. Detailed surgery defini-
tion from SEER data can be found from SEER website
http://seer.cancer.gov/manuals/historic/AppendC.pdf.
Briefly, there are two types of surgeries: breast-conserving
surgery and mastectomy. Breast-conserving surgery was
defined as receiving segmental mastectomy, lumpectomy,
nipple resection, excisional biopsy or partial mastectomy
unspecified, and mastectomy included total, modified
radical, radical, extended radical mastectomy or mastec-
tomy unspecified. Chemotherapy, immunotherapy and
hormonal therapy were not considered since they are not
in the SEER public-use files.
Statistical analysis
The SEER data provide vital status and survival time for
each patient, calculated in months using date of diagnosis
and end of study, either date of death or the end of 2005
(the cut-off date of follow-up), whichever occurred first.
Cause-specific survival was used for the hazard ratios
(HR) estimation. A HR represents the risk of dying from
breast cancer. Women were censored for death from
causes other than breast cancer, or at the end of 2005.
In order to control for the effect of multiple factors simul-
taneously on disparities in breast cancer survival, the
effect of SES on survival was estimated using Cox propor-
tional hazard models. Briefly, these analyses consisted of
six models. The basis model (model 0) estimated HR by
SES without any adjustment using the highest SES group
as a reference. Model 1 adjusted for age group at diagnosis
and year of diagnosis. Ninety-five percent confidence
intervals (CIs) for the HRs were calculated using the esti-
mated coefficients and standard errors from the Cox
regression models. A test of linear hypotheses about the
effect of SES with p-value of < 0.05 was considered to be
statistically significant.BMC Cancer 2009, 9:364 http://www.biomedcentral.com/1471-2407/9/364
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In models two to five, HR for each SES group was esti-
mated with additional adjustment for (2) AJCC stage and
number of positive lymph nodes, (3) first course treat-
ments, (4) race, (5) rural/urban residence at diagnosis,
respectively. This was used to ascertain if adjustment for
each group of factors reduced the survival difference
between SES groups [7,24]. The validity of the propor-
tional hazards of the predictors was tested by stratifying
on the predictors and comparing the parameter estimates
of the stratified model with those from the model includ-
ing the variable as a proportional predictor [25,26]. No
violations of proportionality of hazard were found.
Patient data were obtained using the SEER software
SEER*Stat version 6.4.4. All statistical analyses were per-
formed using SAS 9.1 (SAS Institute, NC).
Results
A total of 112,543 women diagnosed with breast cancer
were included in this analysis. Univariate analysis showed
that all the variables listed in Table 1 were highly associ-
ated with SES level based on area of residence at the time
of diagnosis. As shown in Table 1, women living in the
lowest SES areas had the lowest percentage of early stage
(I): 41.4% vs 45.7-46.7%, and highest percentage of
advanced stages (III, IV): 13.0% vs 9.5-9.9% and were
more likely to have ≥ 4 lymph nodes positive: 16.0% vs
12.3-12.8%. The proportion of Black women living in the
lowest SES areas was nearly four times higher than that of
the highest SES areas: 16.1% vs 4.3%. The proportions of
women from the two lowest SES areas who received the
first course treatment were lower than that of the highest
SES areas, especially for radiation (<48% vs 57.3%). The
proportion living in rural areas for women from lower
middle group was much higher than these of other groups
(23.1% vs <4.0%).
Table 2 shows the results of Cox regression modelling
with an inverse association between SES and risk of dying
from breast cancer (1.00 → 1.05 → 1.23 → 1.31). When
adjusting for age at diagnosis and calendar year (model
Table 1: Distribution of study variables by socioeconomic status (SES), breast cancer diagnosed in 1998-2002
Percentage of area-based SES group
Number of cases Highest SES Upper middle Lower middle Lowest SES p-value
Age at diagnosis (year) <0.0001
15-44 15520 14.4 14.0 12.4 14.4
45-54 26545 25.2 23.3 22.3 23.6
55-64 25545 23.3 23.2 21.9 22.5
65-74 22462 18.6 19.7 21.1 20.3
75+ 22471 18.4 19.8 22.3 19.2
Year of diagnosis <0.0001
1998 22134 19.4 18.4 21.4 19.4
1999 22487 19.5 18.7 21.3 20.1
2000 22385 20.2 21.0 18.6 20.0
2001 22791 20.3 20.9 19.6 20.2
2002 22746 20.6 21.0 19.1 20.3
Race <0.0001
White 92717 90.8 79.7 85.4 74.4
Black 9831 4.3 7.2 6.3 16.1
Other 9995 4.9 13.1 8.3 9.5
Rural/urban residence <0.0001
Rural 9819 2.7 4.0 23.1 4.0
Urban 102724 97.3 96.0 76.9 96.0
AJCC† stage <0.0001
I 50608 46.7 45.7 46.6 41.4
II 41646 36.2 37.1 35.1 39.5
III 7188 5.7 5.8 5.5 8.3
IV 4770 3.8 4.1 4.3 4.7
Unknown 8331 7.6 7.3 8.5 6.2
Number of positive lymph nodes <0.0001
None 60700 64.9 64.0 65.4 60.2
1-3 21948 22.8 23.2 21.9 23.9
≥ 4 12896 12.3 12.8 12.7 16.0
First course treatment received
Surgery 106076 95.3 94.5 93.6 93.8 <0.0001
Radiation 58144 57.3 55.1 47.8 47.7 <0.0001
† AJCC: American Joint Committee on Cancer.BMC Cancer 2009, 9:364 http://www.biomedcentral.com/1471-2407/9/364
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1), the HRs remained significantly higher for women
residing in the two lowest SES areas; women from the low-
est SES areas had 19% higher hazard of cancer-related
death (HR = 1.19) than women from the reference - high-
est SES group (p < 0.0001). After additional adjustment
for stage at diagnosis (model 2), the HR for the lowest SES
group dropped to 1.10, but remained significant. Further
adjustment for first course treatment (model 3) reduced
the HRs for the lowest SES groups slightly (1.10 → 1.08).
Then when adding race to the model (model 4), the HR
for the lowest SES group was non-significant (HR = 1.03,
95% CI: 0.97-1.08). Further, the overall effect of SES was
reduced from highly significant (p < 0.0001) in the base
model to non-significant (p = 0.07) in model 4. Final
adjustment for rural/urban residence (model 5) further
weakened this SES differential (p = 0.20) with no SES
group having significant higher HR than that of the top
SES group.
Race-specific survivals were presented in Figure 1.
Discussion
An inverse association was found between SES and risk of
dying from breast cancer among 112,543 breast cancer
patients. More importantly, stepwise adjustment for stage
at diagnosis, first course treatment, race and rural/urban
residence completely eliminated the survival disparity
associated with lower SES. The strength of this study is
that it considered women of all ages diagnosed with any
stage of breast cancer in SEER database and thus had
much broader coverage and greater statistical power than
previous studies of this issue.
A strength of this study is that the finding of a social asso-
ciation in breast cancer survival was not affected by choice
of data source (17 or 13 SEER registries) or categories of
SES (quintile or quartile, single or composite). This
implies that the models are robust, and the effect of place
of residence was probably real and not due to statistical
artifact. These results were also consistent with many
other studies examining SES disparities in breast cancer
survival in the United States [1,3] and other parts of the
world [7,27]. Further this study is population-based and
includes all women diagnosed with breast cancer in the 13
SEER areas from 1998 to 2002 and followed-up until the
most recent cut-off date - December 31, 2005. Therefore,
these results potentially reflected experiences of the entire
population diagnosed with breast cancer in the 13 SEER
areas and provided a full picture of most recent socioeco-
nomic disparity in breast cancer survival.
This analysis is limited by the allocation of cases to SES
groups using aggregated data. It is possible that individual
people may have been misclassified and the inferences at
Table 2: Hazard ratio (HR) of cancer-specific mortality from breast cancer by socioeconomic status (SES)
Model 0 Model 1 Model 2 Model 3 Model 4 Model 5
Area-based SES 
group
SES only Model 0 + age & 
year
Model 1 + stage Model 2 + 
treatment
Model 3 + race Model 4 + rural/
urban
HR & (CI†) HR & (CI) HR & (CI) HR & (CI) HR & (CI) HR & (CI)
Highest 1.00 1.00 1.00 1.00 1.00 1.00
Upper middle 1.05
(0.99-1.11)
1.01
(0.96-1.07)
1.00
(0.94-1.06)
1.00
(0.95-1.06)
0.99
(0.93-1.05)
0.99
(0.93-1.05)
Lower middle 1.23
(1.16-1.29)
1.09
(1.03-1.15)
1.08
(1.03-1.14)
1.07
(1.01-1.12)
1.06
(1.00-1.12)
1.04
(0.99-1.10)
Lowest 1.31
(1.24-1.38)
1.19
(1.13-1.26)
1.10
(1.04-1.16)
1.08
(1.03-1.14)
1.03
(0.97-1.08)
1.03
(0.97-1.08)
p-value for SES <0.0001 <0.0001 <0.0001 0.003 0.07 0.20
† 95% confidence intervals.
Cause-specific survival from breast cancer diagnosed 1998- 2002 followed-up to 2005 by race Figure 1
Cause-specific survival from breast cancer diagnosed 
1998-2002 followed-up to 2005 by race.BMC Cancer 2009, 9:364 http://www.biomedcentral.com/1471-2407/9/364
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the area level do not directly transfer to individuals. How-
ever, several studies have demonstrated the importance of
area-based socioeconomic measures in measuring health
inequality in the United States [28] and other parts of the
world [7,27]. The second limitation of this study is the
quality and completeness of treatment data in the SEER
database: adjustment for the first course treatment (sur-
gery and radiation) would not necessarily control for all
dimensions of treatment for breast cancer, and in addition
chemotherapy and hormonal therapy data are not availa-
ble in the SEER public-use files. The data was also ana-
lyzed after categorizing receipt of treatment according to
stage at diagnosis, surgery (mastectomy or breast conserv-
ing surgery) and radiation; and it was found that this
grouping did not change the main findings.
Stage at diagnosis explained a large part of the SES dispar-
ity in breast cancer survival. This is likely because women
living in the lowest SES areas had highest percent of
advanced stages (III, IV) and ≥ 4 lymph nodes positive
(Table 1) and much worse survival for those with
advanced stage disease. This unfavorable stage distribu-
tion for women from the lowest SES areas was likely
caused by lower mammography rates. Lack of health
insurance and lower financial resources are known to be
associated with lower mammography rates [8-10,29,30]
and lack of, or delayed follow-up after an abnormal mam-
mogram [31].
The contribution of first course treatment to the SES dif-
ferential in breast cancer survival was rather small in this
study because a large part of this differential had been cap-
tured by the differences in stage distribution between SES
groups; those women diagnosed with later stage disease
are more likely to receive inadequate treatment. However,
possible explanations for women residing in lower SES
areas for receiving inadequate care more often include
lack of health insurance [14], comorbidities [32] and
patients refusal or not adherence to therapies [2,33], and
provider bias [11,34].
The gap in hazard of dying from breast cancer between the
highest and lowest areas was reduced further and the over-
all effect of SES became non-significant (p = 0.07) after
additional adjustment for race (Table 2). This is in part
because blacks were disproportionately represented in the
lowest SES group (16.1%) (Table 1) and had lower sur-
vival rate (Figure 1). However, the contribution of race to
the SES differential in breast cancer survival was modest
because a substantial proportion of SES disparities associ-
ated with race may have been captured by differences in
stage at diagnosis and treatment. Consistent with the wide
literature [3-5,13,18,19,33,35-39], the data indicated that
black women were more likely to have later stages (III, IV)
disease diagnosis (17.1% vs 10.6%) and less likely to
receive first course treatment - surgery (90.3% vs 94.3%)
and radiation (46.0% vs 51.7%) than the general popula-
tion (data not shown). In addition, black women are
more likely to have unfavorable tumor characteristics -
negative hormone receptor status (ER/PR) or HER2-nega-
tive, higher-grade tumors and being diagnosed at younger
age. Lower SES and inadequate access to medical care may
interact with biological factors consequently leading to
the disproportionate number of diagnoses of tumors with
these unfavorable characteristics in younger black
women. A more recent study found that black race was
associated with increased mortality from breast cancer
after adjusting for stage of disease and treatment, the
authors therefore thought that biological or host genetic
factors may be the potential source of the survival gap
[40]. However, other studies reported that black women
still had poorer outcomes from breast cancer after control-
ling for biological factors [1,4,37]. Overall, these data
showed that race picks up some residual effect after con-
trolling for measured variation in stage at diagnosis and
first course treatment, which may be due to measurement
errors, and some factors not related to these two variables,
such as, biological characteristics. However, race is a com-
plex and composite measure of many factors related with
breast cancer survival and this study has limited ability to
separate out these multiple dimensions of race that may
influence survival.
There were some residual survival differentials between
the highest and lower middle groups after adjusting for
stage, first course treatment and race. This may be due to
difference in the use of chemotherapy and/or hormonal
therapy, which are not available in the SEER public-use
data. Several studies found that women living in non-met-
ropolitan areas in the U.S. were more likely to have
delayed initiation of radiotherapy [32] and chemotherapy
[17] after breast cancer surgery. The results of the HR for
lower middle group becoming non-significant after fur-
ther adjustment for rural/urban residence (Table 2),
together with much more women in this group living in
rural areas (Table 1), suggested that factors related to
access to and/or time waiting for chemotherapy and/or
radiotherapy may partly be attributable to the residual
survival difference.
Conclusion
Stage at diagnosis, first course treatment and race
explained most of the socioeconomic disparities in breast
cancer survival. Thus, targeted interventions to increase
breast cancer screening and treatment coverage in patients
with lower SES could reduce much of socioeconomic dis-
parity in breast cancer survival.
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